Atorvastatin improves ovarian function and follicular reserve in rats with premature ovarian insufficiency

IF 3.7 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Reproductive biomedicine online Pub Date : 2024-06-18 DOI:10.1016/j.rbmo.2024.104324

Parmis Notghi, Malek Soleimani Mehranjani, Seyed Mohammad Ali Shariatzadeh

{"title":"Atorvastatin improves ovarian function and follicular reserve in rats with premature ovarian insufficiency","authors":"Parmis Notghi, Malek Soleimani Mehranjani, Seyed Mohammad Ali Shariatzadeh","doi":"10.1016/j.rbmo.2024.104324","DOIUrl":null,"url":null,"abstract":"<div><h3>Research question</h3><p>Can atorvastatin, with its antioxidant, anti-inflammatory and anti-apoptotic properties, improve ovarian function and follicular reserve in rats with cyclophosphamide-induced premature ovarian insufficiency (POI)?</p></div><div><h3>Design</h3><p>In this experimental study, 24 adult female Wistar rats were divided into four groups: control; POI; POI + atorvastatin; and atorvastatin. After treatment with atorvastatin, serum concentrations of total antioxidant capacity, glutathione, malondialdehyde, FSH, oestradiol, anti-Müllerian hormone, tumour necrosis factor-alpha and interleukin-6 were evaluated. Additionally, mRNA and protein expression of Bax, Bcl-2 and VEGF-A; number of follicles; and total volume of the ovary, and volumes of the cortex and medulla were examined.</p></div><div><h3>Results</h3><p>The results showed that serum concentrations of total antioxidant capacity (<em>P</em> < 0.001), glutathione, oestradiol and anti-Müllerian hormone (<em>P</em> < 0.05); mRNA and protein expression of Bcl-2 and VEGF-A (<em>P</em> < 0.05); number of primordial and primary follicles (<em>P</em> < 0.001), and preantral and antral follicles (<em>P</em> < 0.01); and total volume of the ovary, and volume of the cortex (<em>P</em> < 0.05) increased significantly in the POI + atorvastatin group compared with the POI group. Serum concentrations of malondialdehyde, FSH, tumour necrosis factor-alpha and interleukin-6; and mRNA and protein expression of Bax decreased significantly in the POI + atorvastatin group compared with the POI group (<em>P</em> < 0.05).</p></div><div><h3>Conclusions</h3><p>Atorvastatin reduces the detrimental effects of cyclophosphamide in the POI model significantly by reducing oxidative stress and pro-inflammatory cytokines; regulating the expression of Bax, Bcl-2 and VEGF-A; and improving ovarian function and follicular reserve.</p></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproductive biomedicine online","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1472648324005133","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Research question

Can atorvastatin, with its antioxidant, anti-inflammatory and anti-apoptotic properties, improve ovarian function and follicular reserve in rats with cyclophosphamide-induced premature ovarian insufficiency (POI)?

Design

In this experimental study, 24 adult female Wistar rats were divided into four groups: control; POI; POI + atorvastatin; and atorvastatin. After treatment with atorvastatin, serum concentrations of total antioxidant capacity, glutathione, malondialdehyde, FSH, oestradiol, anti-Müllerian hormone, tumour necrosis factor-alpha and interleukin-6 were evaluated. Additionally, mRNA and protein expression of Bax, Bcl-2 and VEGF-A; number of follicles; and total volume of the ovary, and volumes of the cortex and medulla were examined.

Results

The results showed that serum concentrations of total antioxidant capacity (P < 0.001), glutathione, oestradiol and anti-Müllerian hormone (P < 0.05); mRNA and protein expression of Bcl-2 and VEGF-A (P < 0.05); number of primordial and primary follicles (P < 0.001), and preantral and antral follicles (P < 0.01); and total volume of the ovary, and volume of the cortex (P < 0.05) increased significantly in the POI + atorvastatin group compared with the POI group. Serum concentrations of malondialdehyde, FSH, tumour necrosis factor-alpha and interleukin-6; and mRNA and protein expression of Bax decreased significantly in the POI + atorvastatin group compared with the POI group (P < 0.05).

Conclusions

Atorvastatin reduces the detrimental effects of cyclophosphamide in the POI model significantly by reducing oxidative stress and pro-inflammatory cytokines; regulating the expression of Bax, Bcl-2 and VEGF-A; and improving ovarian function and follicular reserve.

查看原文本刊更多论文

阿托伐他汀可改善卵巢早衰大鼠的卵巢功能和卵泡储备功能

阿托伐他汀具有抗氧化、抗炎和抗细胞凋亡的特性，它能改善环磷酰胺诱导的卵巢早衰（POI）大鼠的卵巢功能和卵泡储备吗？在这项实验研究中，24 只成年雌性 Wistar 大鼠被分为四组：对照组；POI 组；POI + 阿托伐他汀组；阿托伐他汀组。阿托伐他汀治疗后，评估了血清中总抗氧化能力、谷胱甘肽、丙二醛、前列腺素、雌二醇、抗苗勒氏激素、肿瘤坏死因子-α和白细胞介素-6的浓度。此外，还检测了 Bax、Bcl-2 和 VEGF-A 的 mRNA 和蛋白表达、卵泡数量、卵巢总体积以及皮质和髓质体积。结果显示，血清总抗氧化能力（< 0.001）、谷胱甘肽、雌二醇和抗苗勒管激素（< 0.05）；Bcl-2 和 VEGF-A 的 mRNA 和蛋白表达（< 0.05）；原始卵泡和初级卵泡数量（< 0.001）、前卵泡和前卵泡（< 0.01）；与 POI 组相比，POI + 阿托伐他汀组的卵巢总体积和皮质体积（< 0.05）显著增加。与 POI 组相比，POI + 阿托伐他汀组的丙二醛、FSH、肿瘤坏死因子-α 和白细胞介素-6 的血清浓度以及 Bax 的 mRNA 和蛋白表达均明显下降（< 0.05）。阿托伐他汀通过减少氧化应激和促炎细胞因子，调节Bax、Bcl-2和VEGF-A的表达，改善卵巢功能和卵泡质量，从而显著降低环磷酰胺对POI模型的不利影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reproductive biomedicine online 医学-妇产科学

CiteScore

7.20

自引率

7.50%

发文量

391

审稿时长

50 days

期刊介绍： Reproductive BioMedicine Online covers the formation, growth and differentiation of the human embryo. It is intended to bring to public attention new research on biological and clinical research on human reproduction and the human embryo including relevant studies on animals. It is published by a group of scientists and clinicians working in these fields of study. Its audience comprises researchers, clinicians, practitioners, academics and patients. Context: The period of human embryonic growth covered is between the formation of the primordial germ cells in the fetus until mid-pregnancy. High quality research on lower animals is included if it helps to clarify the human situation. Studies progressing to birth and later are published if they have a direct bearing on events in the earlier stages of pregnancy.